Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (Epi-RCHOP)

October 8, 2024 updated by: The Lymphoma Academic Research Organisation

A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP

Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21.

Phase II of the study is designed to determine the safety and the efficacy of tazemetostat in DLBCL and FL patients :

DLBCL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab FL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab then maintenance with 6 months of tazemetostat and 24 months of Rituximab

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Phase I:

Up to 18 patients will be recruited, using a conventional dose-escalation algorithm (3+3 patients per dose level) to identify the maximum tolerated dose (MTD) which will be deemed the RP2D. Patients will receive 8 cycles of RCHOP every 21 days and tazemetostat every day, starting on day 2 of cycle 1.

4 cohorts are defined, according to dose levels of tazemetostat: 400mg Twice a day (BID) (cohort 1, starting level), 600mg BID (cohort 2), 800mg BID (cohort 3), 200mg BID (cohort -1), depending on the observed toxicities.

Phase II:

Up to 184 patients (122 DLBCL and 62 FL) will be recruited and treated with tazemetostat at the MTD and RCHOP.

Patients will receive 6 cycles of RCHOP every 21 days and tazemetostat at the MTD every day, starting on day 2 of cyle 1, + 2 cycles of Rituximab+tazemetostat. For FL, a maintenance of tazemetostat (6 months) + rituximab (24 months) is expected

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
214

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Belgium
      • Bruxelles, Belgium
        • Institut Jules Bordet
      • Liege, Belgium
        • CHU de Liège
      • Yvoir, Belgium
        • CHRU Mont Godinne
  • France
      • Argenteuil, France
        • Centre Hospitalier Victor Dupouy
      • Avignon, France
        • CH d'Avignon - Hôpital Henri Dufaut
      • Besançon, France
        • CHU de Besancon - Hopital Jean Minjoz
      • Bordeaux, France
        • Polyclinique Bordeaux Nord Aquitaine
      • Chambéry, France
        • Ch De Chambery
      • Clermont-Ferrand, France
        • CHU d'Estaing
      • Creteil, France
        • APHP - Hopital Henri Mondor
      • Dijon, France
        • CHU de Dijon
      • Grenoble, France
        • CHU Grenoble
      • La Roche sur Yon, France
        • CH départemental de Vendée
      • Lille Cedex, France
        • CHRU Lille - Hôpital Claude Huriez
      • Limoges, France
        • CHU de Limoges - Hôpital Dupuytren
      • Lyon, France
        • Centre Leon Berard
      • Marseille, France
        • Institut Paoli Calmette
      • Montpellier, France
        • CHU de Montpellier - Hopital Saint-Eloi
      • Nantes, France
        • CHU de Nantes - Hotel Dieu
      • Paris, France
        • APHP - Hôpital de la Pitié Salpétrière
      • Paris Cedex 10, France
        • APHP - Hôpital Saint Louis
      • Perpignan, France
        • CH de Perpigan
      • Pierre-Bénite Cedex, France
        • CHU Lyon Sud
      • Poitiers, France
        • Chu de Poitiers - Hopital de Miletrie
      • Rennes, France
        • CHU de Rennes - Hôpital Pontchaillou
      • Rouen, France, 76000
        • Centre Henri Becquerel
      • Saint Cloud, France
        • Centre Rene Hugenin
      • Saint Priest en Jarez, France
        • Institut de Cancerologie de La Loire
      • Strasbourg, France
        • Chru de Strasbourg
      • Toulouse, France
        • Institut Universitaire Du Cancer de Toulouse - Oncopole
      • Villejuif, France
        • Institut Gustave Roussy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

  • INCLUSION CRITERIA

    • for Cohort DLBCL ONLY

      • 1-Patients with an untreated DLBCL de novo or transformed from indolent lymphoma (CD 20 positive) with

        • Phase Ib aaIPI ≥ 2
        • Phase II: aaIPI ≥ 1ONLY
      • 2. Age between 60 and 80 years included

    • for Cohort FOLLICULAR ONLY

      • 1-High Tumor Burden (as defined by GELF criteria > 0) frontline follicular lymphoma (FL) with high risk FLIPI 3-5
      • 2. Aged between 18 years and 80 years included
      • 11bis. Females of childbearing potential (FCBP) must agree to use one reliable form of contraception or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 12 months after discontinuation of any study treatments (R-CHOP, tazemetostat, Rituximab)

    • For both Cohorts

      • 1bis- For phase II patients: Bi-dimensionally measurable disease defined by at least one single node or tumor lesion > 1.5 cm assessed by CT scan and/or clinical examination AND a FDG avid disease by PETscan
      • 3.ECOG performance status of 0, 1 or 2 (0 or 1 only for phase Ib)
      • 4.Signed informed consent
      • 5.Life expectancy of ≥ 90 days (3 months) before starting tazemetostat
      • 6.Adequate renal function as calculated by a creatinine clearance > 40 mL/min by local institutional formula

      • 7. Adequate bone marrow function as defined as:

        • ANC ≥ 1500/mm3 (≥ 1.5 X 109/L)
        • Platelets ≥ 75,000/mm3 (≥ 75 X 109/L) without platelet transfusion dependency during the last 7 days
        • Hemoglobin ≥ 9 g/dL (may receive transfusion)

      • 8. Adequate liver function as defined as:

        • Total bilirubin ≤ 1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome
        • Alkaline phosphatase (in absence of bone disease), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 X ULN (or ≤ 5 X ULN if related to lymphoma involvement)
        • Patients with prior Hepatitis B and C are eligible if, for Hepatitis B detection, surface antigen is negative and/or HBV DNA is undetectable, and for Hepatitis C detection, if HCV RNA is undetectable.
      • 9. Left ventricular ejection fraction (LVEF) ≥ 50% of echocardiography or multiple gated acquisition (MUGA) scan
      • 10. Adequate tissue (surgical excision is recommended) for central pathology review and biological caracterisation (see appendix 11
      • 11. Males with partners of childbearing potential must agree to use reliable forms of contraception during 12 months after last treatment administration
      • 12. Patient covered by any social security system (for France only)
      • 13. Patient who understands and speaks one of the country official languages

  • EXCLUSION CRITERIA

    • for Cohort DLBCL

      ___15-Previous treatment for B cell lymphoma, except glucocorticoids (no more than 7 days before inclusion, 1 mg/kg/day max)

    • for Cohort FOLLICULAR ONLY

      • 14bis. Prior therapy for lymphoma including radiotherapy except glucocorticoids (no more than 7 days before inclusion, 1 mg/kg/day max)
      • 17-Pregnant or lactating females

    • For both Cohorts

      • 1-Central nervous system or meningeal involvement
      • 2-Contraindication to any drug contained in the chemotherapy regimen
      • 3-Prior treatment with tazemetostat or other inhibitor of EZH2
      • 4-Patients who are undergoing active treatment for another malignancy, exceptions include: A patient who has been disease free for 2 years, or a patient with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible Patients with prior history of myeloid malignancies, including myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia(AML) or prior history of T-LBL/T-ALL are excluded whatever receiving treatment or not and whatever date of diagnosis of these pathologies
      • 5-Patients taking medications that are known potent CYP3A4 inducers/inhibitors (including St. John's wort)
      • 6-Patients unwilling to exclude St. John's wort, Seville oranges, grapefruit juice and/or grapefruit from diet
      • 7-Major surgery within 4 weeks before first dose of study drug (minor procedures including transcutaneous biopsy, central line placement are permitted within 2 weeks of enrollment)
      • 8-Inability to take oral medication or malabsorption syndrome or any other uncontrolled gastrointestinal condition that would impare ability to take tazemetostat
      • 9-Significant cardiovascular impairment: congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of first dose of tazemetostat or ventricular arrhythmia
      • 10-Not applicable
      • 11-Active uncontrolled infection requiring systemic therapy
      • 12-Congenital immunodeficiency or known HIV (human immunodeficiency virus infection)
      • 13-Any other major illness, that in the investigator's judgement, will substantially increase the risk associated with the patient's participation in the study
      • 14-Patients who have undergone a solid organ transplant
      • 16-Treatment with any investigational drug or device within 30 days before planned first cycle of chemotherapy
      • 18-Person deprived of his/her liberty by a judicial or administrative decision
      • 19-Adult person under legal protection
      • 20-Person hospitalized without consent
      • 21-Adult person unabled to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: DLBCL cohort

RCHOP + tazemetostat:

- RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1): Phase I : 8 cycles, every 21 days Phase II : 6 cycles, every 21 days

  • Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days
  • Tazemetostat: PO, doses according to dose cohorts for phase I, and at RP2D for phase II: continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID
Drug: Tazemetostat
Tablets 200 mg, to be administrated per os
Other Names:
  • EPZ-6438
Drug: Rituximab
375 mg/m²/dose, D1
Other Names:
  • Mabthera
Drug: Cyclophosphamide
750 mg/m²/dose, D1
Drug: Vincristine
1.4 mg/m²/dose (max 2 mg), D1
Drug: Doxorubicin
50 mg/m²/dose, D1
Drug: Prednisolone
40 mg/m2 in the morning D1 to D5
Experimental: FL cohort

RCHOP + tazemetostat:

Induction

  • RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1):

    6 cycles, every 21 days

  • Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days
  • Tazemetostat: PO, RP2D, continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID

Maintenance

  • Tazemetostat : 6 months (every 8 weeks)
  • Rituximab : 24 months (every 8 weeks)
Drug: Tazemetostat
Tablets 200 mg, to be administrated per os
Other Names:
  • EPZ-6438
Drug: Rituximab
375 mg/m²/dose, D1
Other Names:
  • Mabthera
Drug: Cyclophosphamide
750 mg/m²/dose, D1
Drug: Vincristine
1.4 mg/m²/dose (max 2 mg), D1
Drug: Doxorubicin
50 mg/m²/dose, D1
Drug: Prednisolone
40 mg/m2 in the morning D1 to D5

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Phase I : Number of Dose Limiting Toxicities
Time Frame: 1 cycle (1 cycle is 21 days)
Incidence and severity of treatment-emergent AEs qualifying as protocol defined DLT's in cycle 1 and 2 in order to establish the MTD/RP2D
1 cycle (1 cycle is 21 days)
Phase I : Number of Dose Limiting Toxicities
Time Frame: 2 cycles (1 cycle is 21 days)
Incidence and severity of treatment-emergent AEs qualifying as protocol defined DLT's in cycle 1 and 2 in order to establish the MTD/RP2D
2 cycles (1 cycle is 21 days)
Phase II - DLBCL Cohort : Complete Response Rate based on local assessment
Time Frame: 8 cycles (1 cycle is 21 days)
Complete response rate as determined by Cheson International Work Group (IWG) 2014: Lugano Classification (Deauville scale 1-3)
8 cycles (1 cycle is 21 days)
Phase II - FL Cohort : Complete Response Rate based on local assessment
Time Frame: 8 cycles (1 cycle is 21 days)
Complete response rate as determined by Cheson IWG 2014: Lugano Classification (Deauville scale 1-3)
8 cycles (1 cycle is 21 days)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Phase I : Serum concentration of CHOP components in presence/absence of Tazemetostat
Time Frame: Change between baseline - 1 month
Change between baseline - 1 month
Phase I : Serum concentration of Tazemetostat and its metabolite (EZH 6930) in presence of CHOP
Time Frame: Change between baseline - 1 month
Change between baseline - 1 month
Phase I : Complete response rate (CRR) by central review using Cheson IWG criteria
Time Frame: 8 cycles (1 cycle is 21 days)
8 cycles (1 cycle is 21 days)
Phase II - DLBCL Cohort : Number of Adverse Events (AE)/Serious Adverse Events (SAE)
Time Frame: 8 cycles (1 cycle is 21 days)
8 cycles (1 cycle is 21 days)
Phase II - DLBCL Cohort : Complete response rate (CRR) by central review using Cheson IWG criteria
Time Frame: 8 cycles (1 cycle is 21 days)
8 cycles (1 cycle is 21 days)
Phase II - DLBCL Cohort : Overall response rate (ORR) by central review
Time Frame: 52 weeks
52 weeks
Phase II - DLBCL Cohort : Overall response rate (ORR) by central review
Time Frame: 104 weeks
104 weeks
Phase II - DLBCL Cohort : progression free survival (PFS)
Time Frame: 52 weeks
52 weeks
Phase II - DLBCL Cohort : progression free survival (PFS)
Time Frame: 104 weeks
104 weeks
Phase II - DLBCL Cohort : duration of response (DR)
Time Frame: 52 weeks
52 weeks
Phase II - DLBCL Cohort : duration of response (DR)
Time Frame: 104 weeks
104 weeks
Phase II - DLBCL Cohort : overall survival (OS)
Time Frame: 52 weeks
52 weeks
Phase II - DLBCL Cohort : overall survival (OS)
Time Frame: 104 weeks
104 weeks
Phase II - DLBCL Cohort : best overall response (BOR)
Time Frame: 104 weeks
104 weeks
Phase II - FL cohort : Number of AE/SAE
Time Frame: 8 cycles (1 cycle is 21 days)
8 cycles (1 cycle is 21 days)
Phase II - FL cohort : Number of AE/SAE
Time Frame: 13 months
13 months
Phase II - FL cohort : PET Complete Response Rate (PET-CRR) by central review according to Lugano 2014 criteria
Time Frame: 8 cycles (1 cycle is 21 days)
8 cycles (1 cycle is 21 days)
Phase II - FL cohort : Complete Response Rate (CRR)
Time Frame: 31 months
31 months
Phase II - FL cohort : Overall Response Rate (CRR)
Time Frame: 31 months
31 months
Phase II - FL cohort : Progression Free Survival (PFS)
Time Frame: 24 months
24 months
Phase II - FL cohort : Progression Free Survival (PFS)
Time Frame: 31 months
31 months
Phase II - FL cohort : Event Free Survival (EFS)
Time Frame: 24 months
24 months
Phase II - FL cohort : Overall Survival (OS)
Time Frame: 24 months
24 months
Phase II - FL cohort : Duration of Response (DR)
Time Frame: 31 months
31 months
Phase II - FL cohort : Best Overall Response
Time Frame: 31 months
31 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
The Lymphoma Academic Research Organisation

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Epizyme, Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Vincent Ribrag, MD, Institut Gustave Roussy Cancer Campus Grand Paris
  • Study Chair: Clémentine Sarkozy, MD, Institut Gustave Roussy Cancer Campus Grand Paris
  • Study Chair: Franck Morshhauser, Pr, Centre Régional Hospitalier de Lille
  • Study Chair: Loic Ysebaert, MD, IUCT Oncopole de Toulouse

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2016

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 31, 2023

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 11, 2016

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 30, 2016

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 5, 2016

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 9, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 8, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Epi-RCHOP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphoma

Clinical Trials on Tazemetostat

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings